![Søren Kragh Moestrup](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Søren Kragh Moestrup
Fondatore presso DeLiver Pharma ApS
Posizioni attive di Søren Kragh Moestrup
Società | Posizione | Inizio | Fine |
---|---|---|---|
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Direttore/Membro del Consiglio | 24/07/2013 | - |
Direttore Tecnico/Scientifico/R&S | 24/07/2013 | - | |
DeLiver Pharma ApS
![]() DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Direttore/Membro del Consiglio | - | - |
Fondatore | - | - |
Storia della carriera di Søren Kragh Moestrup
Precedenti posizioni note di Søren Kragh Moestrup
Società | Posizione | Inizio | Fine |
---|---|---|---|
University of Oxford | Corporate Officer/Principal | 01/01/1995 | 01/01/1995 |
Proteopharma AS
![]() Proteopharma AS Pharmaceuticals: MajorHealth Technology Part of 5AM Venture Management LLC, Proteopharma AS is a Danish pharmaceutical company that manufactures pharmaceuticals. The company is based in Aarhus, Denmark. The company was founded by Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. Proteopharma was acquired by Borean Pharma ApS on February 16, 2004. | Fondatore | 01/01/2000 | - |
University of Aarhus | Corporate Officer/Principal | 12/08/2009 | - |
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Amministratore Delegato | 12/08/2009 | - |
Fondatore | 12/08/2009 | 20/05/2014 |
Statistiche
Distribuzione geografica
Danimarca | 6 |
Regno Unito | 2 |
Posizioni
Founder | 3 |
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Proteopharma AS
![]() Proteopharma AS Pharmaceuticals: MajorHealth Technology Part of 5AM Venture Management LLC, Proteopharma AS is a Danish pharmaceutical company that manufactures pharmaceuticals. The company is based in Aarhus, Denmark. The company was founded by Niels Jonas Heilskov Graversen and Søren Kragh Moestrup. Proteopharma was acquired by Borean Pharma ApS on February 16, 2004. | Health Technology |
Cytoguide ApS
![]() Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Health Technology |
DeLiver Pharma ApS
![]() DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | Health Technology |
Affinicon ApS
![]() Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Health Technology |
- Borsa valori
- Insiders
- Søren Kragh Moestrup
- Esperienza